Cargando…

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment

BACKGROUND: The aim of this study was to assess radiomics features on pre-treatment [(18)F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC underwent [(18)F]FDG PET/computed tomo...

Descripción completa

Detalles Bibliográficos
Autores principales: van Helden, E. J., Vacher, Y. J. L., van Wieringen, W. N., van Velden, F. H. P., Verheul, H. M. W., Hoekstra, O. S., Boellaard, R., Menke-van der Houven van Oordt, C. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208805/
https://www.ncbi.nlm.nih.gov/pubmed/30094460
http://dx.doi.org/10.1007/s00259-018-4100-6
_version_ 1783366781294870528
author van Helden, E. J.
Vacher, Y. J. L.
van Wieringen, W. N.
van Velden, F. H. P.
Verheul, H. M. W.
Hoekstra, O. S.
Boellaard, R.
Menke-van der Houven van Oordt, C. W.
author_facet van Helden, E. J.
Vacher, Y. J. L.
van Wieringen, W. N.
van Velden, F. H. P.
Verheul, H. M. W.
Hoekstra, O. S.
Boellaard, R.
Menke-van der Houven van Oordt, C. W.
author_sort van Helden, E. J.
collection PubMed
description BACKGROUND: The aim of this study was to assess radiomics features on pre-treatment [(18)F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC underwent [(18)F]FDG PET/computed tomography (CT) prior to first- or third-line palliative systemic treatment. Tumour lesions were semiautomatically delineated and standard uptake value (SUV), metabolically active tumour volume (MATV), total lesion glycolysis (TLG), entropy, area under the curve of the cumulative SUV-volume histogram (AUC-CSH), compactness and sphericity were obtained. RESULTS: Lesions of 47 patients receiving third-line systemic treatment had higher SUV(max), SUV(peak), SUV(mean), MATV and TLG, and lower AUC-CSH, compactness and sphericity compared to 52 patients receiving first-line systemic treatment. Therefore, first- and third-line groups were evaluated separately. In the first-line group, anatomical changes on CT correlated negatively with TLG (ρ = 0.31) and MATV (ρ = 0.36), and positively with compactness (ρ = −0.27) and sphericity (ρ = −0.27). Patients without benefit had higher mean entropy (p = 0.021). Progression-free survival (PFS) and overall survival (OS) were worse with a decreased mean AUC [hazard ratio (HR) 0.86, HR 0.77] and increase in mean MATV (HR 1.15, HR 1.22), sum MATV (HR 1.14, HR 1.19), mean TLG (HR 1.16, HR 1.22) and sum TLG (HT1.12, HR1.18). In the third-line group, AUC-CSH correlated negatively with anatomical change (ρ = 0.21). PFS and OS were worse with an increased mean MATV (HR 1.27, HR 1.68), sum MATV (HR 1.35, HR 2.04), mean TLG (HR 1.29, HR 1.52) and sum TLG (HT 1.27, HR 1.80). SUV(max) and SUV(peak) negatively correlated with OS (HR 1.19, HR 1.21). Cluster analysis of the 10 radiomics features demonstrated no complementary value in identifying aggressively growing lesions or patients with impaired survival. CONCLUSION: We demonstrated an association between improved clinical outcome and pre-treatment low tumour volume and heterogeneity as well as high sphericity on [(18)F]FDG PET. Future PET imaging research should include radiomics features that incorporate tumour volume and heterogeneity when correlating PET data with clinical outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-4100-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6208805
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-62088052018-11-09 Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment van Helden, E. J. Vacher, Y. J. L. van Wieringen, W. N. van Velden, F. H. P. Verheul, H. M. W. Hoekstra, O. S. Boellaard, R. Menke-van der Houven van Oordt, C. W. Eur J Nucl Med Mol Imaging Original Article BACKGROUND: The aim of this study was to assess radiomics features on pre-treatment [(18)F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC underwent [(18)F]FDG PET/computed tomography (CT) prior to first- or third-line palliative systemic treatment. Tumour lesions were semiautomatically delineated and standard uptake value (SUV), metabolically active tumour volume (MATV), total lesion glycolysis (TLG), entropy, area under the curve of the cumulative SUV-volume histogram (AUC-CSH), compactness and sphericity were obtained. RESULTS: Lesions of 47 patients receiving third-line systemic treatment had higher SUV(max), SUV(peak), SUV(mean), MATV and TLG, and lower AUC-CSH, compactness and sphericity compared to 52 patients receiving first-line systemic treatment. Therefore, first- and third-line groups were evaluated separately. In the first-line group, anatomical changes on CT correlated negatively with TLG (ρ = 0.31) and MATV (ρ = 0.36), and positively with compactness (ρ = −0.27) and sphericity (ρ = −0.27). Patients without benefit had higher mean entropy (p = 0.021). Progression-free survival (PFS) and overall survival (OS) were worse with a decreased mean AUC [hazard ratio (HR) 0.86, HR 0.77] and increase in mean MATV (HR 1.15, HR 1.22), sum MATV (HR 1.14, HR 1.19), mean TLG (HR 1.16, HR 1.22) and sum TLG (HT1.12, HR1.18). In the third-line group, AUC-CSH correlated negatively with anatomical change (ρ = 0.21). PFS and OS were worse with an increased mean MATV (HR 1.27, HR 1.68), sum MATV (HR 1.35, HR 2.04), mean TLG (HR 1.29, HR 1.52) and sum TLG (HT 1.27, HR 1.80). SUV(max) and SUV(peak) negatively correlated with OS (HR 1.19, HR 1.21). Cluster analysis of the 10 radiomics features demonstrated no complementary value in identifying aggressively growing lesions or patients with impaired survival. CONCLUSION: We demonstrated an association between improved clinical outcome and pre-treatment low tumour volume and heterogeneity as well as high sphericity on [(18)F]FDG PET. Future PET imaging research should include radiomics features that incorporate tumour volume and heterogeneity when correlating PET data with clinical outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-018-4100-6) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2018-08-09 2018 /pmc/articles/PMC6208805/ /pubmed/30094460 http://dx.doi.org/10.1007/s00259-018-4100-6 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
van Helden, E. J.
Vacher, Y. J. L.
van Wieringen, W. N.
van Velden, F. H. P.
Verheul, H. M. W.
Hoekstra, O. S.
Boellaard, R.
Menke-van der Houven van Oordt, C. W.
Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
title Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
title_full Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
title_fullStr Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
title_full_unstemmed Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
title_short Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
title_sort radiomics analysis of pre-treatment [(18)f]fdg pet/ct for patients with metastatic colorectal cancer undergoing palliative systemic treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6208805/
https://www.ncbi.nlm.nih.gov/pubmed/30094460
http://dx.doi.org/10.1007/s00259-018-4100-6
work_keys_str_mv AT vanheldenej radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT vacheryjl radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT vanwieringenwn radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT vanveldenfhp radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT verheulhmw radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT hoekstraos radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT boellaardr radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment
AT menkevanderhouvenvanoordtcw radiomicsanalysisofpretreatment18ffdgpetctforpatientswithmetastaticcolorectalcancerundergoingpalliativesystemictreatment